
-

Trial to Test Low-Dose Psilocybin for Mental Distress
A developer of mental health therapies from psychedelic compounds says it received FDA clearance for a clinical trial testing low doses of psilocybin.
-

HPV Vaccine Generates Immune Responses in Trial
Early results from a clinical trial show a vaccine for the human papillomavirus is safe and invokes immune responses in women with low-grade cervical lesions.
-

Infographic – A.I. Venture Funds Tick Up in Q4 2022
A new report on venture funding for artificial intelligence start-ups shows global investment dollars rose in the fourth quarter of 2022, the first increase in 18 months.
-

Standard Electronic Biomarkers Validated for Schizophrenia
A new study validates standard electronic instrument measures of healthy individuals and people with schizophrenia to enable reliable clinical trials for treating the disease.
-

Post-Surgical Fluid Cancer Analytics Company Gains $8M
A start-up company developing liquid biopsies for diagnosing cancer by analyzing fluids drained from a patient after surgery is raising $8 million in seed funds.
-
Music Influences Your Mood, and Other Benefits
Music can be an influence in many ways and it’s something that is worth understanding psychologically.
-

Trial Shows Electronic Dressing Stops Biofilm Infections in Burns
Findings from a clinical trial show a dressing for burns with an electric current prevents formation of bacterial films, reducing risks of infections.
-

Remote Monitoring Shown to Reduce COPD Hospital Visits
A study of people with COPD shows patients using a wearable electronic device to report health status have fewer unplanned hospital visits than before using the device.
-

Gene Therapy Shown to Build Knee Cartilage
Findings from research with lab animals shows a single gene therapy injection delivered with a benign virus helps build new knee cartilage cells and tissue.
-

Infographic – Tech Layoffs Jump This Year
Since the start of 2023, layoffs in technology industries worldwide rose markedly, continuing a trend that began in the fall of 2022.